142 related articles for article (PubMed ID: 35906610)
21. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients.
Son JW; Jeong KJ; Jean WS; Park SY; Jheon S; Cho HM; Park CG; Lee HY; Kang J
Cancer Lett; 2011 Dec; 311(1):29-37. PubMed ID: 21757291
[TBL] [Abstract][Full Text] [Related]
22. Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.
Tanaka I; Morise M; Miyazawa A; Kodama Y; Tamiya Y; Gen S; Matsui A; Hase T; Hashimoto N; Sato M; Hasegawa Y
Clin Lung Cancer; 2020 May; 21(3):273-280.e4. PubMed ID: 32088115
[TBL] [Abstract][Full Text] [Related]
23. A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.
Li J; Li X; Zhang C; Zhang C; Wang H
Oncol Rep; 2020 Mar; 43(3):795-806. PubMed ID: 32020214
[TBL] [Abstract][Full Text] [Related]
24. Specific Lung Squamous Cell Carcinoma Prognosis-Subtype Distinctions Based on DNA Methylation Patterns.
Huang G; Zhang J; Gong L; Liu D; Wang X; Chen Y; Guo S
Med Sci Monit; 2021 Mar; 27():e929524. PubMed ID: 33661858
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
Wu F; Lu M; Qu L; Li DQ; Hu CH
Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
[TBL] [Abstract][Full Text] [Related]
26. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
[TBL] [Abstract][Full Text] [Related]
27. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in
West HJ; McCleland M; Cappuzzo F; Reck M; Mok TS; Jotte RM; Nishio M; Kim E; Morris S; Zou W; Shames D; Das Thakur M; Shankar G; Socinski MA
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190375
[TBL] [Abstract][Full Text] [Related]
28. The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer.
Shibata Y; Kobayashi N; Sato T; Nakashima K; Kaneko T
Thorac Cancer; 2020 May; 11(5):1258-1264. PubMed ID: 32163231
[TBL] [Abstract][Full Text] [Related]
29. [Current progression of bevacizumab in advanced non-small cell lung cancer].
Chu TQ; Chen JH; Han BH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):793-800. PubMed ID: 30392346
[TBL] [Abstract][Full Text] [Related]
30. DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer.
Wang Z; Chen Z; Gao Y; Li N; Li B; Tan F; Tan X; Lu N; Sun Y; Sun J; Sun N; He J
Cancer Biol Ther; 2011 Mar; 11(5):490-6. PubMed ID: 21383543
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer.
Chen DT; Hsu YL; Fulp WJ; Coppola D; Haura EB; Yeatman TJ; Cress WD
J Natl Cancer Inst; 2011 Dec; 103(24):1859-70. PubMed ID: 22157961
[TBL] [Abstract][Full Text] [Related]
33. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
[TBL] [Abstract][Full Text] [Related]
34. Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
Hakozaki T; Okuma Y; Hashimoto K; Hosomi Y
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2555-2564. PubMed ID: 31350622
[TBL] [Abstract][Full Text] [Related]
35. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma.
Luo R; Song J; Xiao X; Xie Z; Zhao Z; Zhang W; Miao S; Tang Y; Ran L
Aging (Albany NY); 2020 Jul; 12(14):14649-14676. PubMed ID: 32723974
[TBL] [Abstract][Full Text] [Related]
36. Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.
Mo ML; Ma J; Chen Z; Wei B; Li H; Zhou Y; Shi H; Tolani B; Jin JQ; Tseng HH; Shen D; Zhan Y; Li J; Jablons DM; Zhang RQ; Guo Y; He B; Zhou HM
J Cancer Res Clin Oncol; 2015 May; 141(5):901-8. PubMed ID: 25367137
[TBL] [Abstract][Full Text] [Related]
37. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
Botta C; Barbieri V; Ciliberto D; Rossi A; Rocco D; Addeo R; Staropoli N; Pastina P; Marvaso G; Martellucci I; Guglielmo A; Pirtoli L; Sperlongano P; Gridelli C; Caraglia M; Tassone P; Tagliaferri P; Correale P
Cancer Biol Ther; 2013 Jun; 14(6):469-75. PubMed ID: 23760488
[TBL] [Abstract][Full Text] [Related]
38. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
[TBL] [Abstract][Full Text] [Related]
39. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD; Lee JW; Carbone DP; Wagner H; Shanker A; de Aquino MTP; Horn L; Johnson ML; Gerber DE; Liu JJ; Das MS; Al-Nsour MA; Dakhil CSR; Ramalingam S; Schiller JH
Clin Lung Cancer; 2020 Nov; 21(6):520-526. PubMed ID: 32807654
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
